Quest PharmaTech Inc. — Capital/Financing Update 2022

Jun 27, 2022

==> picture [162 x 48] intentionally omitted <==

==> picture [150 x 75] intentionally omitted <==

June 27, 2022

VIA SEDAR

To the Securities Regulatory Authorities in each Province and Territory of Canada

RE: Canadian Imperial Bank of Commerce

Dear Sirs/Mesdames:

We refer you to Pricing Supplement No. 1,169 dated June 27, 2022 (the “Supplement”) to a short form base shelf prospectus dated September 17, 2021 relating to the offering of up to $50,000,000 of CIBC Autocallable Notes linked to Canadian Indices (AR) Portfolio, Series 65 (F-Class).

We hereby consent to the reference to our name on the face page and the reference to our name and opinions in the summary in Appendix C – “Certain Canadian Federal Income Tax Considerations” to the Supplement.

We confirm that we have read the Supplement and that we have no reason to believe that there are any misrepresentations (as defined in the Securities Act (Ontario)) in the information contained in the Supplement that are derived from our opinions referred to above or that are within our knowledge as a result of services we performed in connection with the preparation of such opinions.

Yours very truly,

“ Blake, Cassels & Graydon LLP ”

==> picture [391 x 17] intentionally omitted <==

13149101.1